June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
|Videos|January 24, 2021
Analyzing effects of corneal biomechanics on IOP
Author(s)David Hutton, Alex Delaney-Gesing
Robert L. Stamper, MD, discusses the findings of a study analyzing the effects of corneal mechanics on IOP, presented during the virtual Glaucoma 360 meeting.
Advertisement
Advertisement
Related to this article
Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial upside beyond the US.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Tinlarebant in Stargardt disease: Jacque Duncan, MD, on DRAGON results
2
AAO 2026: Vamikibart shows sustained gains in uveitic macular edema as FDA accepts BLA
3
PRIMA at 3 years: Early surgical risk, durable vision gains in GA
4
AAO 2026: What the evidence really shows about nutrition and the eye
5